Pharmaceutical group · United States
Amgen
A group of 20 companies with 519 medicines in 10 countries.
Loading your page…
Loading your page…
Pharmaceutical group · United States
A group of 20 companies with 519 medicines in 10 countries.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
20 companies in 10 countries
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
1–25 of 519
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Aimovig70mg/ml · Injection | Erenumab | United States | Not marketed | 2018 |
| Aimovig140mg/ml · Injection | Erenumab | United States | Marketed | 2019 |
| AIMOVIG70mg/ml · Injectable | Erenumab | United States | Marketed | 2018 |
| Aimovig140mg/ml · Injection | Erenumab | United States | Not marketed | 2019 |
| AMGEVITASoluzione iniettabile | Adalimumab | Italy | Authorised | |
| AMGEVITA50 mg / ml · Solution | Adalimumab | Canada | Marketed | 2021 |
| AMGEVITA50 mg / ml · Solution | Adalimumab | Canada | Marketed | 2021 |
| AMGEVITA80 mg / 0.8 ml · Solution | Adalimumab | Canada | Authorised | |
| AMGEVITA40 mg / 0.4 ml · Solution | Adalimumab | Canada | Authorised | |
| AMGEVITA50 mg / ml · Solution | Adalimumab | Canada | Marketed | 2021 |
| AMGEVITA | Adalimumab | Brazil | Authorised | 2019 |
| AMGEVITA80 mg / 0.8 ml · Solution | Adalimumab | Canada | Authorised | |
| Amgevita | Adalimumab | EU (EMA) | Authorised | 2017 |
| AMGEVITA20 mg / 0.2 ml · Solution | Adalimumab | Canada | Authorised | |
| AMGEVITA40 mg / 0.4 ml · Solution | Adalimumab | Canada | Authorised | |
| Amgevita 20 mg, oplossing voor injectie in een voorgevulde spuitOplossing voor injectie | Adalimumab | Netherlands | Authorised | 2024 |
| Amgevita 20 mg, oplossing voor injectie in een voorgevulde spuitOplossing voor injectie | Adalimumab | Netherlands | Authorised | 2017 |
| AMGEVITA 20 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA20 mg · Solución inyectable | Adalimumab | Spain | Marketed | 2024 |
| AMGEVITA 20 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA20 mg · Solución inyectable en jeringa precargada | Adalimumab | Spain | Authorised | 2018 |
| Amgevita 40 mg, oplossing voor injectie in een voorgevulde penOplossing voor injectie | Adalimumab | Netherlands | Authorised | 2024 |
| Amgevita 40 mg, oplossing voor injectie in een voorgevulde penOplossing voor injectie | Adalimumab | Netherlands | Authorised | 2017 |
| Amgevita 40 mg, oplossing voor injectie in een voorgevulde spuitOplossing voor injectie | Adalimumab | Netherlands | Authorised | 2024 |
| Amgevita 40 mg, oplossing voor injectie in een voorgevulde spuitOplossing voor injectie | Adalimumab | Netherlands | Authorised | 2017 |
| AMGEVITA 40 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA40 mg · Solución inyectable | Adalimumab | Spain | Marketed | 2024 |
| AMGEVITA 40 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA40 mg · Solución inyectable en jeringa precargada | Adalimumab | Spain | Authorised | 2018 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 100 | 91 | 9 | CompaniesAll medicines |
| United States | 93 | 93 | 0 | CompaniesAll medicines |
| Canada | 79 | 67 | 12 | CompaniesAll medicines |
| Netherlands | 78 | 78 | 0 | CompaniesAll medicines |
| Saudi Arabia | 32 | 32 | 0 | CompaniesAll medicines |
| European Union (EMA) | 29 | 21 | 8 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
ANVISA / CMED, consumer price table; embedded source date 2026-07-21 and retrieval date
Licence: Other (Public Domain)
Anvisa published factual open-data CSV https://dados.anvisa.gov.br/dados/CONSULTAS/PRODUTOS/TA_CONSULTA_MEDICAMENTOS.CSV, HTTP version Mon, 12 Oct 2026 11:45:25 GMT; acquired 12 October 2026; original source states and timestamps retained.
Licence: Brazil federal factual open data, consolidated Decreto 8777/2016 article 4; attribution and third-party exceptions
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
| Romania | 29 | 0 | 29 | CompaniesAll medicines |
|---|
| Singapore | 29 | 29 | 0 | CompaniesAll medicines |
|---|
| Brazil | 28 | 23 | 5 | CompaniesAll medicines |
|---|
| Italy | 22 | 22 | 0 | CompaniesAll medicines |
|---|
Also in the registers of France, Serbia, United Kingdom
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Ministerul Sănătății, Catalogul public naţional al preţurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licence: Serbian Open Data Licence (sodl)
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Contains information from ACRA Information on Corporate Entities, accessed on 8 October 2026 through Data.gov.sg, under Singapore Open Data Licence version 1.0: https://data.gov.sg/open-data-licence. Structured selection and normalisation by Prognia; original UEN, field and retrieval date retained.
Licence: Singapore Open Data Licence
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
Register právnických osôb, podnikateľov a orgánov verejnej moci; public API licence names Štatistický úrad Slovenskej republiky; administration transferred to Ministerstvo vnútra SR; original API URL, literal identifier and source locators, source version and retrieval date; https://creativecommons.org/licenses/by/4.0/; normalization identified.
Licence: Creative Commons Attribution
Slovak Ministry of Finance, Register účtovných závierok (RÚZ) Open API; exact IČO/accounting-unit, filing, report and template IDs; original API URLs, source locators and retrieval dates; https://www.registeruz.sk/cruz-public/home/api; extraction/normalization stated.
Licence: CC0
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.